Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
This agreement is in addition to the $92 million filling line expansion announced in November 2021
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The AI and technology upgrades allow doctors to choose their medical speciality and even spelling preferences to set their own speech model
Subscribe To Our Newsletter & Stay Updated
